BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24470514)

  • 41. Immunogenic targets in non-small cell lung cancer: more is more.
    Gnjatic S
    Clin Cancer Res; 2005 Aug; 11(15):5331-2. PubMed ID: 16061843
    [No Abstract]   [Full Text] [Related]  

  • 42. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy for lung cancer: for whom the bell tolls?
    Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current immunotherapeutic strategies in lung cancer.
    Rüttinger D; Hatz RA; Jauch KW; Fox BA
    Surg Oncol Clin N Am; 2007 Oct; 16(4):901-18, x. PubMed ID: 18022551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
    Custodio A; de Castro J
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S19-28. PubMed ID: 26477471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immuno-Oncology therapeutic principles in lung and renal cell carcinoma].
    Wolf J; Grünwald V
    Oncol Res Treat; 2014; 37 Suppl 4():10-3. PubMed ID: 25301191
    [No Abstract]   [Full Text] [Related]  

  • 50. Vaccines and immunotherapy for non-small cell lung cancer.
    Morgensztern D; Goodgame B; Govindan R
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S463-5. PubMed ID: 21102240
    [No Abstract]   [Full Text] [Related]  

  • 51. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
    Rijavec E; Genova C; Alama A; Barletta G; Sini C; Pronzato P; Coco S; Dal Bello MG; Savarino G; Truini A; Boccardo F; Grossi F
    Future Oncol; 2014 Jan; 10(1):79-90. PubMed ID: 24328411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent clinical trials of immunotherapy in non-small-cell lung cancer.
    Gkolfinopoulos S; Mountzios G
    Immunotherapy; 2019 Apr; 11(6):461-466. PubMed ID: 30860438
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunotherapy in the treatment of non-small cell lung cancer.
    Bílek O; Bořilová S; Grell P; Kiss I
    Klin Onkol; 2021; 34(Supplementum 1):54-64. PubMed ID: 34154331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytokine immunotherapy of non-small cell lung cancer.
    Dubinett SM; Kradin RL
    Reg Immunol; 1993; 5(3-4):232-43. PubMed ID: 8240940
    [No Abstract]   [Full Text] [Related]  

  • 55. Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?
    Rossi A
    Expert Rev Vaccines; 2013 Jan; 12(1):5-7. PubMed ID: 23256734
    [No Abstract]   [Full Text] [Related]  

  • 56. Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer.
    Limacher JM; Spring-Giusti C; Bellon N; Ancian P; Rooke R; Bonnefoy JY
    Expert Rev Vaccines; 2013 Mar; 12(3):263-70. PubMed ID: 23496666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy Comes of Age in Lung Cancer.
    Khanna P; Blais N; Gaudreau PO; Corrales-Rodriguez L
    Clin Lung Cancer; 2017 Jan; 18(1):13-22. PubMed ID: 27461776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The state of the art in non-small cell lung cancer immunotherapy.
    Seetharamu N
    Semin Thorac Cardiovasc Surg; 2014; 26(1):26-35. PubMed ID: 24952755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The role of immune checkpoint inhibitors in lung cancer: from clinical trials to clinical practice].
    Wang ZM; Song Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):95-99. PubMed ID: 32062879
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-small-cell lung cancer vaccine therapy: a concise review.
    O'Mahony D; Kummar S; Gutierrez ME
    J Clin Oncol; 2005 Dec; 23(35):9022-8. PubMed ID: 16219932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.